Anacor Pharmaceuticals Price Target Raised to $8.00 at Canaccord Genuity (ANAC)
Investment analysts at Canaccord Genuity boosted their target price on shares of Anacor Pharmaceuticals (NASDAQ: ANAC) from $5.00 to $8.00 in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock.
Anacor Pharmaceuticals (NASDAQ: ANAC) traded up 25.62% on Friday, hitting $6.08. Anacor Pharmaceuticals has a 52-week low of $3.00 and a 52-week high of $7.18. The stock’s 50-day moving average is currently $3.61. The company’s market cap is $216.3 million.
Anacor Pharmaceuticals (NASDAQ: ANAC) last released its earnings data on Thursday, March 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. The company had revenue of $3.28 million for the quarter, compared to the consensus estimate of $3.25 million. During the same quarter in the prior year, the company posted ($0.52) earnings per share. The company’s quarterly revenue was up 26.6% on a year-over-year basis. On average, analysts predict that Anacor Pharmaceuticals will post $-1.58 earnings per share for the current fiscal year.
Separately, analysts at Wedbush raised their price target on shares of Anacor Pharmaceuticals from $10.00 to $20.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.